Skip to main content
Terug
Watch Compare

Indaptus Therapeutics, Inc.

Datakwaliteit: 83%
INDP
NASDAQ Manufacturing Chemicals
€ 2,33
▲ € 0,27 (13,11%)
6 months return
—
Momentum
Neutral
ROE
-1421,98%

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-1421,98%
Onder sectorgemiddelde (-54,68%)
ROIC-1068,66%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio2,88
Interest CoverageN/A

Waardering

PE (TTM)
-0,20
Boven sectorgemiddelde (-1,50)
P/B Ratio0,90
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -14,82 M

Price History

Financiële Trends

Koersdoel Analisten

1 analist
Hold
+329.2%
upside to target
Huidig
€ 2,33
Consensus Target
€ 10,00
€ 10,00
Laag
€ 10,00
Hoog
Vooruitzicht
Forward WPA
-€ 4,48
Omzet Sch.
0,0

Winstverassingen

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -€ 1,87 · Rev Est: 0,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -€ 8,96 -€ 9,09 -€ 2,98 -€ 9,19 — —
Estimate -€ 5,04 -€ 9,24 -€ 4,17 -€ 4,36 -€ 1,87 -€ 1,57
Verrassing -77,78% +1,62% +28,54% -110,78% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -1421,98% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -20,85 M
ROE -1421,98% ROA -304,83%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -14,82 M
ROIC -1068,66% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 2,88
Debt / Equity N/A Current Ratio 2,88
Interest Coverage N/A Asset Turnover N/A
Working Capital 4,20 M Tangible Book Value 4,61 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0,20 · EV/EBITDA: N/A
P/E Ratio -0,20 Forward P/E N/A
P/B Ratio 0,90 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -357,33%
Market Cap 4,15 M Enterprise Value -1,68 M

Per Share

EPS: -21,58 · FCF/Share: -6,61
EPS (Diluted TTM) -21,58 Revenue / Share N/A
FCF / Share -6,61 OCF / Share -6,61
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 71,10% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 71,10%
SBC-Adj. FCF -15,84 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -20,85 M -15,02 M -15,42 M -14,32 M -7,71 M
EPS (Diluted) -21,58 -1,61 -1,83 — —
Gross Profit — — — — —
Operating Income -19,83 M -15,37 M -16,38 M -14,91 M -7,73 M
EBITDA — — — — —
R&D Expenses 9,34 M 7,25 M 7,62 M 6,32 M 2,52 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax 1.716,0 1.700,0 2.450,0 30,0 1.650,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 9,31 M 7,34 M 14,92 M 28,06 M 40,58 M
Total Liabilities — 3,39 M 2,85 M 3,43 M 4,68 M
Shareholders' Equity 3,15 M 3,94 M 12,08 M 24,63 M 35,90 M
Total Debt — — — — —
Cash & Equivalents 8,51 M 5,79 M 13,36 M 9,63 M 39,13 M
Current Assets 9,31 M 6,62 M 14,00 M 27,24 M 40,39 M
Current Liabilities 6,16 M 3,39 M 2,77 M 3,43 M 4,60 M

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -0,2 -1,5
P/B 0,9 1,6
ROE % -1422,0 -54,7
Net Margin % — -41,5
Rev Growth 5Y % — 1,7
D/E — 0,3